Venture Certified
| 벤처투자유형 | 2023-09-13 ~ 2026-09-12 | 20230913010013 | 2023-09-13 |
| Item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0.0B | 0.0B | 0.0B |
| Operating Profit | -13B | -8.4B | -3.1B |
| Net Profit | -13B | -7.4B | -2.6B |
| Total Assets | 18B | 21B | 28B |
| Total Liabilities | 11B | 0.4B | 0.1B |
| Total Equity | 7.1B | 20B | 27B |
Operating Loss: Op. profit -13B
3 Consecutive Years of Net Loss
Debt Ratio Surge (+151pp YoY)
- 0.0%
▼ 130.9%
▲ 11333.4%
▼ 689.0%
| Name | Position | Role |
|---|---|---|
| 임옥재, 신의철 | 대표이사 | 대표 |
| Regular Employees | 6persons |
| CEO | 임옥재, 신의철 |
No Data – Contact
No procurement record or data not yet available| Tax Type | 부가가치세 일반과세자 |
| Status | Cert. flags confirmed (details update after further collection) |
2 Additional Data Sources
{
"address": "충청북도 청주시",
"ceo_name": "임옥재, 신의철",
"certificate": [
{
"cert_number": "20230913010013",
"changes": "대표자, 소재지",
"disclosure_date": "2023-09-13",
"first_cert_date": "2023-09-13",
"no": "1",
"type": "벤처투자유형",
"valid_period": "2023-09-13 ~ 2026-09-12"
}
],
"company_name": "티쎌로지 주식회사",
"financials": {
"2022": {
"capital_stock": 12500000,
"cost_of_sales": 0,
"current_assets": 2585635000,
"current_liabilities": 13073000,
"gross_profit": 0,
"net_income": -257716000,
"net_income_bs": -257716000,
"non_current_assets": 174119000,
"non_current_liabilities": 0,
"non_operating_expenses": 0,
"non_operating_income": 53452000,
"operating_profit": -311168000,
"revenue": 0,
"sga_expenses": 311168000,
"total_assets": 2759754000,
"total_equity": 2746681000,
"total_liabilities": 13073000
},
"2023": {
"capital_stock": 12500000,
"cost_of_sales": 0,
"current_assets": 1468007000,
"current_liabilities": 15095000,
"gross_profit": 0,
"net_income": -735856000,
"net_income_bs": -735856000,
"non_current_assets": 587080000,
"non_current_liabilities": 29167000,
"non_operating_expenses": 0,
"non_operating_income": 105820000,
"operating_profit": -841676000,
"revenue": 0,
"sga_expenses": 841676000,
"total_assets": 2055087000,
"total_equity": 2010825000,
"total_liabilities": 44262000
},
"2024": {
"capital_stock": 12499000,
"cost_of_sales": 0,
"current_assets": 1181265000,
"current_liabilities": 1038116000,
"gross_profit": 0,
"net_income": -1296210000,
"net_income_bs": -1296210000,
"non_current_assets": 627022000,
"non_current_liabilities": 55556000,
"non_operating_expenses": 5264000,
"non_operating_income": 40127000,
"operating_profit": -1331073000,
"revenue": 0,
"sga_expenses": 1331073000,
"total_assets": 1808287000,
"total_equity": 714615000,
"total_liabilities": 1093672000
}
},
"industry": "의학 및 약학 연구개발업",
"investment": [
{
"amount": "1,500,000,000",
"changes": "1,500,000,000",
"date": "2021-12-01"
},
{
"amount": "1,500,000,000",
"changes": "1,500,000,000",
"date": "2021-12-01"
}
],
"phone": "031-698-****",
"source": "pg_migration"
}{
"address": "충청북도 청주시 흥덕구 오송읍 오송생명1로 194-25 (3층 A-13호)",
"employee_count": 6,
"establishment_date": "20230501",
"source": "pg_migration",
"workplace_name": "티쎌로지주식회사"
}Data Quality: 80/10 | Primary Source: Venture System | Section Coverage: 7/8
| Section | Source: | Status |
|---|---|---|
| Basic Info | Public Data | Collected |
| Financial Statements | Venture System | Collected |
| Investment Metrics | Not Collected | Not Collected |
| Officers | Public Data | Collected |
| Employment | Public Data | Collected |
| Certifications | Public Data | Collected |
| Patents | KIPRIS | Collected |
| Procurement | G2B Procurement | Collected |
| API | Collected | Status |
|---|---|---|
| Venture System Detail | 2026-03-05 | Collected |
| comwel_insurance | 2026-03-05 | Collected |
| G2B Procurement | 2026-02-25 | Collected |
| Employment Insurance | 2026-02-25 | Collected |
| KIPRIS Patents | 2026-02-25 | Collected |
| HomeTax Business | 2026-02-25 | Collected |
| Cert. Info | 2026-02-25 | Collected |